Corticotropin-releasing factor antagonists: Therapeutic potential in the treatment of affective disorders

CNS Drugs

Volumn 12, Issue 2, 1999, Pages 85-92

  Owens, Michael J ^a   Nemeroff, Charles B ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [N (2 BROMO 4 ISOPROPYLPHENYL) N ETHYLAMINO] 4 [4 (3 FLUOROPHENYL) 1,2,3,6 TETRAHYDRO 1 PYRIDINYL] 6 METHYLPYRIMIDINE; 3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; 4 [4 (3 FLUOROPHENYL) 1,2,3,6 TETRAHYDRO 1 PYRIDINYL] 2 [N ETHYL N (4 ISOPROPYL 2 METHYLTHIOPHENYL)AMINO] 6 METHYLPYRIMIDINE; 5 CHLORO 4 [N (CYCLOPROPYLMETHYL) N PROPYLAMINO] 2 METHYL 6 (2,4,6 TRICHLOROANILINO)PYRIMIDINE; 8 (2,4 DICHLOROPHENYL) 4 [2 METHOXY 1 (METHOXYMETHYL)ETHYLAMINO] 2,7 DIMETHYLPYRAZOLO[1,5 A][1,3,5]TRIAZINE; ANTALARMIN; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR; RECEPTOR SUBTYPE; SC 241; UNCLASSIFIED DRUG;

AFFECTIVE NEUROSIS; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NEUROMODULATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECEPTOR DENSITY; REVIEW; STRESS; TISSUE DISTRIBUTION;

EID: 0032835094     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199912020-00001     Document Type: Review

References (40)

1. 1. Vale W, Speiss J, Rivier C, et al. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 1981; 213: 1394-7
2. 2. Owens MJ, Nemeroff CB. Physiology and pharmacology of corticotropin releasing factor. Pharmacol Rev 1991; 43: 425-73
3. 3. Heit S, Owens MJ, Plotsky PM, et al. Corticotropin-releasing factor, stress, and depression. The Neuroscientist 1997; 3: 186-94
4. 4. Chalmers DT, Lovenberg TW, Grigoriadis DE, et al. Corticotrophin-releasing factor receptors: from molecular biology to drug design. Trends Pharmacol Sci 1996; 17: 166-72
5. 5. Vaughan J, Donaldson C, Bittencourt J, et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 1995; 378: 287-92
6. 2 receptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues. Endocrinology 1995; 136: 4139-42
7. 7. Richard D, Rivest R, Naimi N, et al. Expression of corticotropin-releasing factor and its receptors in the brain of lean and obese Zucker rats. Endocrinology 1996; 137: 4786-95
8. 2 receptors in nonhuman primate brain. J Comp Neurol 1999; 408: 365-77
9. 9. Arborelius L, Owens MJ, Plotsky PM, et al. The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 1990; 160: 1-12
10. 10. Nemeroff CB. The neurobiology of depression. Sci Am 1998; 278 (6): 42-9
11. 11. Plotsky PM, Owens MJ, Nemeroff CB. Psychoneuroendocrinology of depression: hypothalamic-pituitary-adrenal axis. Psychiatr Clin North Am 1998; 21: 293-307
12. 12. Liaw CW, Grigoriadis DE, Lovenberg TE, et al. Localization of ligand binding domains of the human corticotropin-releasing factor receptor: a chimeric receptor approach. Mol Endocrinol 1997; 11: 980-5
13. 13. Liaw CW, Grigoriadis DE, Lorang MT, et al. Localization of agonist and antagonist binding domains of human corticotropin-releasing factor receptors. Mol Endocrinol 1997; 11: 2048-53
14. 14. Christos TE, Arvantis A. Corticotrophin-releasing factor receptor antagonists. Exp Opin Ther Pat 1998; 8: 143-52
15. 15. Schulz DW, Mansbach RS, Sprouse J, et al. CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc Natl Acad Sci U S A 1996; 93: 10477-82
16. 16. Lundkvist J, Chai Z, Teheranian R, et al. A non peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activity. Eur J Pharmacol 1996; 309 (2): 195-200
17. 1 receptor antagonist. Eur J Pharmacol 1997; 323: 21-6
18. 1 receptor attenuates stress-induced relapse to drug seeking in cocaine- and heroin-trained rats. Psychopharmacology 1998; 137: 184-90
19. 1 antagonist. J Med Chem 1997; 40: 1749-54
20. 20. Webster EL, Lewis DB, Torpy DJ, et al. In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation. Endocrinology 1996; 137: 5747-50
21. 21. Bornstein SR, Webster EL, Torpy DJ, et al. Chronic effects of a nonpeptide corticotropin-releasing hormone type I receptor antagonist on pituitary-adrenal function, body weight, and metabolic regulation. Endocrinology 1998; 139: 1546-55
22. 22. Deak T, Nguyen KT, Ehrlich AL, et al. The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress. Endocrinology 1999; 140: 79-86
23. 1 antagonists. Ann Rep Med Chem 1997; 32: 41-50
24. 2 receptors: membrane homogenate and autoradiographic studies. J Pharmacol Exp Ther 1998; 286 (1): 459-68
25. 25. Arvanitis AG, Gilligan PJ, Chorvat RJ, et al. Non-peptide corticotropin-releasing hormone antagonists: syntheses and structure-activity relationships of 2-anilinopyrimidines and -triazines. J Med Chem 1999; 42: 805-18
26. 26. Chorvat RJ, Bakthavatchalam R, Beck J, et al. Synthesis corticotropin-releasing factor receptor binding affinity, and pharmacokinetic properties of triazolo-, imidazolo-, and pyrrolopyrimidines and -pyridines. J Med Chem 1999; 42: 833-48
27. 27. Hodge CN, Aldrich PE, Wasserman ZR, et al. Corticotropin-releasing hormone antagonists: framework design and synthesis guided by ligand conformation studies. J Med Chem 1999; 42: 819-32
28. 28. Kalin NH, Shelton SE, Zaczek R. The evaluation of CRF receptor antagonists in animal models [abstract]. In: Proc Am Coll Neuropsychopharmacol. Nashville (TN): American College of Neuropsychopharmacology, 1997: 19
29. 29. Hindman C, Dent G, McElroy JF, et al. Effects of a non-peptide CRH antagonist on the HPA axis. Neuroendocrine Workshop on Stress sponsored by the Am Neuroendocrine Soc: 1998 Jun 21-23; New Orleans, LA: 42
30. 30. Maciag C, Dent G, He L, et al. Non-peptide corticotropin releasing factor antagonists mitigate behavioral sequelae of maternal separation. Neuroendocrine Workshop on Stress sponsored by the Am Neuroendocrine Soc: 1998 Jun 21-23; New Orleans, LA: 43
31. 1 receptor antagonists: identification and pharmacological characterization. Neuroendocrine Workshop on Stress sponsored by the Am Neuroendocrine Soc: 1998 Jun 21-23; New Orleans, LA: 38
32. 1 receptor antagonists. J Med Chem 1996; 39: 4358-60
33. 1 receptor antagonists. J Med Chem 1996; 39: 4354-7
34. 1 receptor mediates the excitatory actions of corticotropin releasing factor (CRF) in the developing rat brain in vivo: evidence using a selective non-peptide receptor antagonist [abstract no. 689.9]. Soc Neurosci Abstr 1997; 23: 1764
35. 1 receptor antagonist: NBI 27914 [abstract no. 689.10]. Soc Neurosci Abstr 1997; 23: 1764
36. 36. Arai K, Ohata H, Shibasaki T. Non-peptidic corticotropin-releasing hormone receptor type 1 antagonist reverses restraint stress-induced shortening of sodium pentobarbital-induced sleeping time of rats: evidence that an increase in arousal induced by stress is mediated through CRH receptor type 1. Neurosci Lett 1998; 255: 103-6
37. 37. Okuyama S, Chaki S, Kawashima N, et al. Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001. J Pharmacol Exp Ther 1999; 289: 926-35
38. 1 receptor antagonists. CRA1000 and CRA1001. Eur J Pharmacol 1999; 371: 205-11
39. 1 receptor antagonists [abstract]. In: Proc Am Coll Neuropsychopharmacol. Nashville (TN): American College of Neuropsychopharmacology, 1997: 19
40. 40. Grigoriadis DE, De Souza EB. Small molecule CRF1 receptor antagonists: characterization and clinical application. Neuroendocrine workshop on stress sponsored by the am neuroendocrine soc: 1998 Jun 21-23; New Orleans, LA: 36